美诺华：获得厄贝沙坦氢氯噻嗪片药品注册证书

Core Insights - Meinuo Pharma (603538) announced that its wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd., has received the drug registration certificate for Irbesartan Hydrochlorothiazide Tablets from the National Medical Products Administration [1] Group 1 - The approved drug is indicated for the treatment of primary hypertension [1]